The approach of fall is when doctors normally begin reminding patients to think about getting the flu vaccine, and now they are also reminding patients about the new COVID-19 vaccines that were recently approved.

The new COVID-19 vaccines are recommended for everyone six months of age and older. The U.S. Food and Drug Administration approved the vaccines, from manufacturers Pfizer and Moderna, on Thursday, August 22. The annual influenza vaccine is also recommended for those six months and older.

You should think about getting both vaccines before the end of September, according to Bernard Camins, MD, MSC, Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai and the Medical Director for Infection Prevention for the Mount Sinai Health System.

“The immune response from the COVID-19 vaccine can wane after a few months, so that’s why people should get the most current vaccine and be ready for the fall surge,” Dr. Camins says.

Those at risk for developing severe disease from COVID-19 should think about getting the new vaccines within the next month, according to Dr. Camins. This includes older adults, those with chronic medical conditions, such as diabetes, heart disease, chronic lung disease and those with reduced ability to fight infections, such as organ transplant recipients and those being treated for cancer.

You may find it easier to get your new COVID-19 vaccine and flu shot at the same time. However, if you want to get them one after the other, you should start with the COVID-19 vaccine, because the peak flu season usually occurs later than the COVID-19 surge, according to Dr. Camins.

Flu vaccines are important because the flu is contagious and can lead to serious illness, hospitalization, and even death, according to the U.S. Centers for Disease Control and Prevention (CDC).

Experts say getting the new COVID-19 vaccine is important now because the number of cases generally surges as colder temperatures arrive and people spend more time indoors, especially during the holidays.

In addition, the new COVID-19 vaccines have been developed to provide the best protection against the newest subvariants. The vaccines you may have gotten last year were developed for different strains. COVID-19 vaccines typically provide protection for up to 20 weeks before their effectiveness begins to decline.

Many private insurance plans, along with Medicare and Medicaid, cover the cost of COVID-19 vaccines.  You can find more information from the New York City Department of Health about where to get the new COVID-19 vaccines.

Based on last year’s data, the COVID-19 vaccines will prevent COVID-19 in about half of people. But more importantly, they are more effective in preventing serious illness and hospitalizations for those who do become infected. They can also help you avoid complications from long COVID.

For kids, it’s important to get the COVID-19 vaccine because younger people can also have complications if they get infected, plus they can bring home infections where they can affect other family members who may be more at risk.

Meanwhile, your best defense against a COVID-19 infection remains the same: Keep up to date with your vaccinations, consider taking steps to limit your exposure to large indoor crowds, wear a well-fitting mask at public gatherings or in tight spaces such as an airplane or public transportation, and talk with your health care provider if you are feeling sick.

There is a third vaccine that older adults should consider getting, and that is for RSV (respiratory syncytial virus). RSV is a common respiratory virus that infects the lungs, but can also affect the nose and throat.

RSV spreads in the fall and winter along with other respiratory viruses, like flu and COVID-19. RSV usually peaks in December and January, according to the CDC. The CDC recommends the RSV vaccine for adults 75 years and older, and for adults 60 to 74 who are at increased risk for getting severe infections. You do not need to get the RSV vaccine every year.

The battle against Alzheimer’s disease is advancing rapidly, thanks to groundbreaking research from the Icahn School of Medicine at Mount Sinai and other institutions around the world. Where there was once a bleak landscape—where diagnosis came too late and with very limited treatment options—there is now hope for researchers, clinicians, and patients as new drugs and imaging technologies become available. With the advancement of diagnostic tools, the research community has its sights set on an even more ambitious goal: preventing or delaying Alzheimer’s disease before it ever takes hold.

“We need more data from a diverse range of people to fully realize the potential of these biomarkers,” says Dr. Sano. “The general public needs to know about these biomarkers, and how they can make them more powerful by participating in research studies.”

What are blood biomarkers and how are they linked to Alzheimer’s disease?

In the past, detecting Alzheimer’s and related degenerative diseases required invasive procedures, like spinal taps, and was typically reserved for patients already experiencing symptoms of cognitive decline. While these work-ups–or comprehensive tests– measure certain proteins, or biomarkers, that are telltale signs of the disease, they silo brain health from the rest of the body, says Dr. Elahi.

Now, researchers and physicians understand that what is present in the brain can be detected in the rest of the body, including blood, opening up new possibilities for early diagnosis. Key blood biomarkers linked to Alzheimer’s include:

• Hyperphosphorylated tau: One hallmark of Alzheimer’s disease is amyloid beta plaque buildup in the brain, and elevated levels of hyperphosphorylated tau in the blood is predictive of amyloid beta brain accumulation. This biomarker can accelerate the diagnosis and help guide the work-up that lead to treatment decisions.
• Neurofilament light (NfL): This structural protein found in neurons and axons is shed when axons degenerate, and is one of the earliest known biomarkers of brain degeneration for Alzheimer’s and other related dementia disorders. NfL levels can provide valuable insight into the disease’s progression
• Glial fibrillary acidic protein (GFAP): This protein is highly expressed by specialized brain cells called astrocytes. Approved by the Food and Drug Administration as a biomarker for traumatic brain injury, several studies show that levels of GFAP are also elevated in patients with Alzheimer’s disease and related dementias.

“We are learning so much, but we need more participants to help use fine-tune these biomarkers,” says Dr. Sano. “We’re on the cusp of making these tools useful to clinicians and to the broader public.”

How you can help make preventive screening a reality

Participating in Alzheimer’s research is a vital step toward turning these promising biomarkers into reliable tools for prevention. Signing up for an Alzheimer’s disease research center registry is a good start, says Dr. Sano. The team at Mount Sinai will reach out to interested individuals offering various ways to participate.

Diversity in these studies is crucial.  “Different factors, like comorbidities, can influence biomarker levels, and we need to understand these nuances,” says Dr. Elahi. Historically, Alzheimer’s research has been predominantly white-centric, but the disease affects people of all backgrounds. To create effective screening tools, the research community needs participants from a wide range of medical, socioeconomic, gender, age, race, and ethnic backgrounds.

“We need to shift our thinking from treating Alzheimer’s disease to preventing it,” says Dr. Sano. This message is going to be important for people in their 30s, 40s, and 50s, so they can take appropriate steps, such as screening or adjusting lifestyle habits, to reduce or delay the risk.

“New tools, such as blood biomarkers, that push the frontier of early detection will impact what we learn about the causes of disease and eventually revolutionize treatments,” says Dr. Elahi.